AllianceBernstein’s MoonLake Immunotherapeutics MLTX Stock Holding History

AllianceBernstein’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,138,022	Closed	-$53.7M	–	3280
2025 Q2	$53.7M	Buy	1,138,022 +171,932	+18%	+$7M	0.02%	582
2025 Q1	$37.7M	Sell	966,090 -56,514	-6%	-$2.44M	0.01%	657
2024 Q4	$55.4M	Buy	1,022,604 +24,464	+2%	+$1.25M	0.02%	564
2024 Q3	$50.3M	Sell	998,140 -23,610	-2%	-$1.11M	0.02%	599
2024 Q2	$44.9M	Buy	1,021,750 +66,243	+7%	+$2.81M	0.02%	625
2024 Q1	$48M	Buy	955,507 +46,356	+5%	+$2.51M	0.02%	610
2023 Q4	$54.9M	Buy	909,151 +437,832	+93%	+$22.6M	0.02%	556
2023 Q3	$26.9M	Sell	471,319 -366,440	-44%	-$20.2M	0.01%	758
2023 Q2	$42.7M	Buy	+837,759	New	+$22.5M	0.02%	613

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

AllianceBernstein's MLTX Position: Q3 2025 in Review

AllianceBernstein sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 1,138,022 shares — an estimated $53.7M sold.

AllianceBernstein first reported a position in MLTX in Q2 2023 and held it in 9 quarters. The position peaked at $55.4M in Q4 2024. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

AllianceBernstein reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
AllianceBernstein sold 1,138,022 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $53.7M.
AllianceBernstein first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 9 quarters.
AllianceBernstein's MoonLake Immunotherapeutics position peaked at $55.4M in Q4 2024.
134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on AllianceBernstein's 13F filing for Q3 2025, filed 14 Nov 2025.